logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Injectable Drug Delivery Devices Market, By Type (Devices, Formulation), By Therapeutic Use (Autoimmune, Hormonal, Oncology, Others) By End User (Hospital, Homecare Setting and Others) opportunities and forecast 2020-2027

  • DLR2168
  • 19 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

The increasing number of various chronic diseases such as cancer and diabetes has fuelled the need for various injectable drug delivery. Contrasting other traditional forms of the drug delivery, injectable allow supreme bioavailability of pharmaceutical drug as bypasses first pass metabolism. With considerable growth in the technological advancements, devices being marketed and manufactured are built so to cater to the precise needs of the patients.

With the initiation of self-injection devices, the injectable drugs can be self-administered without medical assistance. Large number of such technology-oriented advances have taken place in biologics market, which supplementary increases applicability of injectable devices in challenging disease areas. These self-injection devices have permitted patients suffering from the diabetes to manage the insulin levels with various pen-injectors, auto-injectors, and needle-free injectors; therefore, the homecare settings has been increasing in the end-user application.

Segment Overview

The homecare settings or application of such devices has been most profit garnering section with a large group of patients suffering from the chronic diseases and therefore, resulting in high utility of the devices at primary level for the better management and control of the disease.

Regional Overview

North America is anticipated to lead market for these drug delivery devices with largest number of patients suffering from various chronic diseases such as diabetes and cancer with autoimmune disorders. North America is leading is due to advanced research and technological innovations in the area that permit them to top at designing improved and new drug delivery products.

The Asia Pacific market, on the other hand, is set to lead remarkably well owing to partnerships with other established global players. The region has also witnessed huge investments in R&D; thus, increasing the growth of the injectable market in APAC.

Competitor overview

Key factors increasing competition are fast adoption of various advanced devices for the improved healthcare. Additionally, the major players are often undertaking mergers and acquisitions along with the new product launches to retain their share and diversify product portfolio.

Key Players
  1. Pfizer, Inc.,
  2. Schott AG,
  3. Becton, Dickinson and Company,
  4. Baxter International, Inc.,
  5. ELI Lilly & Co.

Market Segmentation

By Type
  • Devices
    • Self- injection devices
    • Conventional injection devices
  • Formulation
    • Conventional Drug Delivery
    • Novel Drug Delivery
    • Others
By Therapeutic Use
  • Autoimmune disorders
  • Hormonal disorders
  • Oncology
  • Others
By End User
  • Hospitals
  • Homecare Settings
  • Others
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 17

    2 Market Introduction 19

    • 2.1 Scope of Study 20
    • 2.2 Research Objective 20
    • 2.3 List of Assumptions 20

    3 Research Methodology 22

    • 3.1 Research Process 23
    • 3.2 Primary Research 24
    • 3.3 Secondary Research 25
    • 3.4 Market Size Estimation 26

    4 Market Dynamics 27

    • 4.1 Introduction 28
    • 4.2 Drivers 29
      • 4.2.1 Increasing prevalence of chronic diseases 29
      • 4.2.2 Growing adoption of self-injectable devices 29
      • 4.2.3 Rising FDA approvals 29
      • 4.2.4 Drivers Impact Analysis 30
    • 4.3 Restraints 30
      • 4.3.1 Risks of cross-contamination 30
      • 4.3.2 Increasing cost of high-end products 30
      • 4.3.3 Restraints Impact Analysis 31
    • 4.4 Opportunity 31
      • 4.4.1 Increasing campaigns of vaccination in developing economies of the Asia-Pacific region 31
    • 4.5 Macroeconomic Indicators 31
    • 4.6 Market Trend 32
      • 4.6.1 Increasing use of auto-injectors against allergies 32

    5 Market Factor Analysis 33

    • 5.1 Value Chain Analysis 34
      • 5.1.1 R&D and Designing 34
      • 5.1.2 Manufacturing 34
      • 5.1.3 Distribution & Sales 34
      • 5.1.4 Post-Sales Review 35
    • 5.2 Porter’s Five Forces Model 35
      • 5.2.1 Threat of New Entrants 35
      • 5.2.2 Bargaining Power of Suppliers 36
      • 5.2.3 Threat of Substitutes 36
      • 5.2.4 Bargaining Power of Buyers 36
      • 5.2.5 Intensity of Rivalry 36
    • 5.3 Investment Opportunities 36
    • 5.4 Pricing Analysis 37
    • 5.5 Demand & Supply: Gap Analysis 37

    6 Global Injectable Drug Delivery Devices Market, By Devices 38

    • 6.1 Introduction 39
    • 6.2 Conventional Injection Devices 40
    • 6.3 Self-Injection Devices 42

    7 Global Injectable Drug Delivery Devices Market, By Therapeutic Application 43

    • 7.1 Introduction 44
    • 7.2 Autoimmune Diseases 45
    • 7.3 Hormonal Disorders 45
    • 7.4 Cancer 45

    8 Global Injectable Drug Delivery Devices Market, By Usage Pattern 46

    • 8.1 Introduction 47
    • 8.2 Curative pattern 48
    • 8.3 Immunization 48

    9 Global Injectable Drug Delivery Devices Market, By Site of Delivery 49

    • 9.1 Introduction 50
    • 9.2 Intramuscular 51
    • 9.3 Subcutaneous 51
    • 9.4 Intra Dermal 51

    10 Global Injectable Drug Delivery Devices Market, By Distribution Channel 52

    • 10.1 Introduction 53
    • 10.2 Hospital & Retail Pharmacies 54
    • 10.3 Online Platforms 54

    11 Global Injectable Drug Delivery Devices Market, By Facility of Use 55

    • 11.1 Introduction 56
    • 11.2 Hospitals and Clinics 57
    • 11.3 Home Care Settings 57

    12 Global Injectable Drug Delivery Devices Market, By Region 58

    • 12.1 Introduction 59
    • 12.2 Americas 60
      • 12.2.1 North America 63
        • 12.2.1.1 U.S 66
        • 12.2.1.2 Canada 68
        • 12.2.1.3 South America 71
  • 12.3 Europe 74
    • 12.3.1 Western Europe 77
      • 12.3.1.1 Germany 80
      • 12.3.1.2 U.K 83
      • 12.3.1.3 France 86
      • 12.3.1.4 Italy 88
      • 12.3.1.5 Spain 91
      • 12.3.1.6 Rest of Western Europe 94
    • 12.3.2 Eastern Europe 97
  • 12.4 Asia Pacific 100
    • 12.4.1 Japan 103
    • 12.4.2 China 106
    • 12.4.3 India 108
    • 12.4.4 Republic of Korea 111
    • 12.4.5 Australia 114
    • 12.4.6 Rest of Asia Pacific 117
  • 12.5 Middle East & Africa 120
    • 12.5.1 Middle East 123
    • 12.5.2 Africa 126
  • 13 Competitive Landscape 129

    • 13.1 Introduction 130

    14 Company Profile 131

    • 14.1 Eisai Co., Ltd. 132
      • 14.1.1 Company Overview 132
      • 14.1.2 Financial Overview 132
      • 14.1.3 Products Offering 133
      • 14.1.4 Key Developments 133
      • 14.1.5 SWOT Analysis 133
      • 14.1.6 Key Strategy 133
    • 14.2 Antares Pharma 134
      • 14.2.1 Company Overview 134
      • 14.2.2 Financial Overview 134
      • 14.2.3 Products Offering 135
      • 14.2.4 Key Developments 135
      • 14.2.5 SWOT Analysis 135
      • 14.2.6 Key Strategy 135
    • 14.3 AstraZeneca 136
      • 14.3.1 Company Overview 136
      • 14.3.2 Financial Overview 136
      • 14.3.3 Pipeline Products 137
      • 14.3.4 Key Developments 137
      • 14.3.5 SWOT Analysis 137
      • 14.3.6 Key Strategy 137
    • 14.4 Becton, Dickinson and Company 138
      • 14.4.1 Company Overview 138
      • 14.4.2 Financial Overview 138
      • 14.4.3 Products Offering 139
      • 14.4.4 Key Developments 139
      • 14.4.5 SWOT Analysis 140
      • 14.4.6 Key Strategy 140
    • 14.5 Eli Lilly and Company 141
      • 14.5.1 Company Overview 141
      • 14.5.2 Financial Overview 141
      • 14.5.3 Products Offering 142
      • 14.5.4 Key Developments 142
      • 14.5.5 SWOT Analysis 142
      • 14.5.6 Key Strategy 142
    • 14.6 F. Hoffmann-La Roche AG 143
      • 14.6.1 Company Overview 143
      • 14.6.2 Financial Overview 143
      • 14.6.3 Products Offering 144
      • 14.6.4 Key Developments 144
      • 14.6.5 SWOT Analysis 144
      • 14.6.6 Key Strategy 144
    • 14.7 Johnson & Johnson Services Inc. 145
      • 14.7.1 Company Overview 145
      • 14.7.2 Financial Overview 145
      • 14.7.3 Products Offering 146
      • 14.7.4 Key Developments 146
      • 14.7.5 SWOT Analysis 146
      • 14.7.6 Key Strategy 146
    • 14.8 Mylan N.V. 147
      • 14.8.1 Company Overview 147
      • 14.8.2 Financial Overview 147
      • 14.8.3 Products Offering 148
      • 14.8.4 Key Developments 148
      • 14.8.5 SWOT Analysis 148
      • 14.8.6 Key Strategy 148
    • 14.9 Novartis AG 149
      • 14.9.1 Company Overview 149
      • 14.9.2 Financial Overview 149
      • 14.9.3 Products Offering 150
      • 14.9.4 Key Developments 150
      • 14.9.5 SWOT Analysis 150
      • 14.9.6 Key Strategy 150
    • 14.10 Novo Nordisk 151
      • 14.10.1 Company Overview 151
      • 14.10.2 Financial Overview 151
      • 14.10.3 Products Offering 152
      • 14.10.4 Key Developments 152
      • 14.10.5 SWOT Analysis 152
      • 14.10.6 Key Strategy 152
    • 14.11 Pfizer Inc. 153
      • 14.11.1 Company Overview 153
      • 14.11.2 Financial Overview 153
      • 14.11.3 Products Offering 154
      • 14.11.4 Key Developments 154
      • 14.11.5 SWOT Analysis 154
      • 14.11.6 Key Strategy 154
    • 14.12 Sanofi 155
      • 14.12.1 Company Overview 155
      • 14.12.2 Financial Overview 155
      • 14.12.3 Products Offering 156
      • 14.12.4 Key Developments 156
      • 14.12.5 SWOT Analysis 156
      • 14.12.6 Key Strategy 156
    • 14.13 Teva Pharmaceutical Industries Ltd 157
      • 14.13.1 Company Overview 157
      • 14.13.2 Financial Overview 157
      • 14.13.3 Products Offering 158
      • 14.13.4 Key Developments 158
      • 14.13.5 SWOT Analysis 158
      • 14.13.6 Key Strategy 158
    • 14.14 Inovio Pharmaceuticals Inc. 159
      • 14.14.1 Company Overview 159
      • 14.14.2 Financial Overview 159
      • 14.14.3 Products Offering 160
      • 14.14.4 Key Developments 160
      • 14.14.5 SWOT Analysis 160
      • 14.14.6 Key Strategy 160

    15 Appendix 161

    • 15.1 Discussion Blue Print 162

    Report You Might be Interested